135 related articles for article (PubMed ID: 22996653)
1. MYC addiction: a potential therapeutic target in MM.
Kuehl WM; Bergsagel PL
Blood; 2012 Sep; 120(12):2351-2. PubMed ID: 22996653
[TBL] [Abstract][Full Text] [Related]
2. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
3. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
4. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma.
Ye T; Mishra AK; Banday S; Li R; Hu K; Coleman MM; Shan Y; Chowdhury SR; Zhou L; Pak ML; Simone TM; Malonia SK; Zhu LJ; Kelliher MA; Green MR
Cell Rep; 2024 May; 43(5):114211. PubMed ID: 38722741
[TBL] [Abstract][Full Text] [Related]
5. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
8. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.
Yu Z; Li T; Wang C; Deng S; Zhang B; Huo X; Zhang B; Wang X; Zhong Y; Ma X
Oncotarget; 2016 Mar; 7(13):15725-37. PubMed ID: 26894970
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.
Yao R; Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Gao J; Xu K
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30068698
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
[TBL] [Abstract][Full Text] [Related]
11. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Aird F; Kandela I; Mantis C;
Elife; 2017 Jan; 6():. PubMed ID: 28100400
[TBL] [Abstract][Full Text] [Related]
12. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma.
Xiao X; Gu Y; Wang G; Chen S
Int J Biol Macromol; 2019 Feb; 122():526-537. PubMed ID: 30389523
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
14. Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.
Siegel DS; Terry JA; Koury J; Barlogie B; Epstein J; Feinman R
Curr Top Microbiol Immunol; 1997; 224():257-60. PubMed ID: 9308249
[No Abstract] [Full Text] [Related]
15. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
[TBL] [Abstract][Full Text] [Related]
16. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2015 Sep; 6(26):22698-705. PubMed ID: 26087190
[TBL] [Abstract][Full Text] [Related]
17. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
18. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
[TBL] [Abstract][Full Text] [Related]
19. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
[TBL] [Abstract][Full Text] [Related]
20. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
Chem Res Toxicol; 2024 Jun; 37(6):1062-1069. PubMed ID: 38815162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
